{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:11:50Z","timestamp":1791180710194,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4140,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Acute hepatitis C often progresses to chronic infection. We undertook a randomized controlled trial to determine whether short-term therapy with interferon (IFN) during acute hepatitis C is effective in preventing the development of chronic hepatitis. Thirty patients with acute hepatitis C were randomized into 1 of 2 treatment groups. IFN therapy was initiated 8 weeks after the onset of acute hepatitis in the early-intervention group and after 1 year of observation in the late-intervention group. Short-term therapy consisted of natural IFN-alfa (6 million units) administered on consecutive days for a period of 4 weeks. Any signs of recrudescence of disease were immediately followed by interval IFN therapy (3 times weekly for 20 weeks). In the early-intervention group, short-term therapy was associated with a sustained virological response in 13 of 15 patients (87%). Follow-up treatment was associated with a sustained virological response in both of the remaining 2 patients (100%). The sustained virological response rate was significantly higher in the early-intervention group (87%, 13 of 15 patients after short-term therapy alone, and 100%, 15 of 15 patients after short-term with or without follow-up therapy) than in the late-intervention group (40%, 6 of 15 patients after short-term therapy alone, and 53%, 8 of 15 patients after short-term therapy with or without follow-up therapy, <jats:italic toggle=\"yes\">P<\/jats:italic> = .021 and <jats:italic toggle=\"yes\">P<\/jats:italic> = .006, respectively). In conclusion, short-term (4 weeks) IFN treatment of patients with acute hepatitis C may be associated with satisfactory results, if initiated at an early stage of the disease. (Hepatology 2004;39:1213-1219.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.20196","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T23:01:43Z","timestamp":1083020503000},"page":"1213-1219","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":130,"title":["Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial"],"prefix":"10.1097","volume":"39","author":[{"given":"Hideyuki","family":"Nomura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suketo","family":"Sou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seizaburo","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20241201","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.","volume":"22","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"R2-7-20241201","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/hep.1840210308","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients.","volume":"21","author":"Takano","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R3-7-20241201","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b.","volume":"15","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"R4-7-20241201","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/jhep.2003.50019","article-title":"Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.","volume":"37","author":"Hofer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R5-7-20241201","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R6-7-20241201","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","article-title":"Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.","volume":"29","author":"Ikeda","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R7-7-20241201","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/hep.510270529","article-title":"Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.","volume":"27","author":"Kasahara","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R8-7-20241201","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/jhep.2003.50329","article-title":"Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.","volume":"38","author":"Imazeki","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R9-7-20241201","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1023\/A:1024196201684","article-title":"Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin.","volume":"48","author":"Arif","year":"2003","journal-title":"Dig Dis Sci"},{"key":"R10-7-20241201","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"26","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-7-20241201","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R12-7-20241201","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0140-6736(91)91774-O","article-title":"Resolution of acute hepatitis C after therapy with natural beta interferon.","volume":"338","author":"Omata","year":"1991","journal-title":"Lancet"},{"key":"R13-7-20241201","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.1840150504","article-title":"Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial.","volume":"15","author":"Viladomiu","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R14-7-20241201","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0016-5085(94)90130-9","article-title":"Effects of interferon beta on non-A, non-B acute hepatitis: a prospective randomized, controlled-dose study.","volume":"107","author":"Takano","year":"1994","journal-title":"Gastroenterology"},{"key":"R15-7-20241201","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.1840190105","article-title":"A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.","volume":"19","author":"Lampertico","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R16-7-20241201","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0168-8278(94)80246-7","article-title":"A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.","volume":"21","author":"Hwang","year":"1994","journal-title":"J Hepatol"},{"key":"R17-7-20241201","first-page":"1041","article-title":"Interferon therapy for acute post-transfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status.","volume":"86","author":"Ohnishi","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"R18-7-20241201","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/hep.1840190538","article-title":"A proposed system for the nomenclature of hepatitis C virus genotypes.","volume":"19","author":"Simmonds","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R19-7-20241201","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004836-199901000-00013","article-title":"Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick.","volume":"28","author":"Oketani","year":"1999","journal-title":"J Clin Gastroenterol"},{"key":"R20-7-20241201","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(01)06356-5","article-title":"Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.","volume":"358","author":"Jessner","year":"2001","journal-title":"Lancet"},{"key":"R21-7-20241201","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0163-4453(97)94339-5","article-title":"Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay.","volume":"34","author":"Nomura","year":"1997","journal-title":"J Infect"},{"key":"R22-7-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004836-199804000-00009","article-title":"Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response.","volume":"26","author":"Yamaji","year":"1998","journal-title":"J Clin Gastroenterol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.20196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200405000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T11:33:29Z","timestamp":1733052809000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200405000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.20196","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}